BREATHNINE SYRUP 2MG5ML

Land: Maleisië

Taal: Engels

Bron: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Koop het nu

Bijsluiter Bijsluiter (PIL)
20-10-2021
Productkenmerken Productkenmerken (SPC)
08-06-2022

Werkstoffen:

SALBUTAMOL SULPHATE

Beschikbaar vanaf:

SM PHARMACEUTICALS SDN. BHD.

INN (Algemene Internationale Benaming):

SALBUTAMOL SULPHATE

Eenheden in pakket:

100ml mL; 60ml mL

Geproduceerd door:

SM PHARMACEUTICALS SDN. BHD.

Bijsluiter

                                PLEASE REFER TO E12
                                
                                Lees het volledige document
                                
                            

Productkenmerken

                                Package Insert
Page 1 of 5
SM PHARMACEUTICALS SDN. BHD.
BREATHNINE (SALBUTAMOL SULPHATE) SYRUP 2 MG / 5 ML
DESCRIPTION:
A clear, red coloured liquid with sweet taste and raspberry flavour.
COMPOSITION:
Salbutamol Sulphate equivalent to 2mg / 5ml Salbutamol.
ACTIONS AND MODE OR MECHANISMS OF ACTION:
A direct-acting sympathomimetic amine. Acts relatively selectively on
beta 2 adrenergic
receptors in the lungs to relax bronchiol smooth muscle, thereby
relieving bronchospasm
and reducing airway resistance. Also relaxes smooth muscle of the
uterus and vascular
supply to the skeletal muscle. These actions are believed to result
from increased
production of cyclic adenosine 3'5' monophosphate (cylic 3'5' -AMP)
caused by activation
of the enzyme adenyl cyclase.
PHARMACOLOGY
(SUMMARY
OF
PHARMACODYNAMICS
AND
PHARMACOKINETICS):
Absorption - Well absorbed from the gastrointestinal tract.
Metabolism - Hepatic, primarily to salbutamol 4'-0 sulfate which has
little or no beta-
adrenergic blocking activity..
Half life - (plasma) 2.7 to 5 hours.
Onset of action - within 30 minutes
Time to peak plasma concentration - within 2 to 3 hours following a 6
mg of tritiated
salbutamol sulphate.
Time to peak effect – 2 to 3 hours.
Duration of action – 6 hours or longer.
Excretion - Renal; approximately 76% of oral dose excreted over 3 days
in the urine, the
majority of dose being excreted within the first 24 hours, consisting
of 60% as metabolites.
Faecal; About 4% of oral dose may be excreted in the faeces.
INDICATIONS:
a. Relief of broncial asthma
b. Chronic bronchitis
c. Emphysema
d. Acute dyspnea
CONTRAINDICATIONS:
Use of this medication should be carefully considered when the
following medical
problems exist (reasons given where appropriate).
Cardiovascular disorders, including coronary insufficiency and
hypertension.
Package Insert
Page 2 of 5
Diabetes mellitus, Enlarged prostate, Hyperthyroidism.
SIDE EFFECTS / ADVERSE REACTIONS:
Fine
tremor
(usually
hands),
nervous
tension,
headache,
peripheral
vasodilation,
tachycardia (seldom
                                
                                Lees het volledige document
                                
                            

Documenten in andere talen

Bijsluiter Bijsluiter Maleis 06-06-2017

Zoekwaarschuwingen met betrekking tot dit product

Bekijk de geschiedenis van documenten